Agenus Inc. (AGEN) Discusses Zydus Collaboration, Global Manufacturing Expansion, and Patient Access Initiatives Transcript

Stefanie Perna-Nacar
Chief Communications & Government Relations Officer

Good afternoon, everyone, and thank you for joining us today. I’m Stefanie Nacar, Chief Communications Officer at Agenus, and welcome to our first stakeholder webcast of 2026. Today’s discussion comes at a meaningful moment for our company, one shaped by important progress across patient access, clinical development and operational readiness as we enter a pivotal year for Agenus and for the patients we serve.

Before we begin, a brief reminder that today’s discussion will include forward-looking statements. These are subject to risks and uncertainties that could cause actual results to differ. So please refer to our SEC filings for additional detail. Today’s program is designed to reflect the full arc of momentum we are seeing globally from manufacturing and execution to expanded patient access to the clinical evidence needed to support regulatory pathways.

You’ll hear perspectives from leaders who are directly shaping this progress. Garo and I will discuss recently closed Zydus collaboration and what enables operationally for Agenus, an expert clinical perspective on the expansion of France’s reimbursed AAC program, including its relevance for sarcomas and insight into how growing physician and patient interest is reshaping our medical affairs infrastructure to support access responsibly and at scale.

Following these discussions, Agenus’ leadership, including Dr. Steven O’Day, our Chief Medical Officer; Jose Iglesias, our Chief Medical Affairs Officer; and Robin Taylor, our Chief Commercial Officer, will join Garo for a live Q&A session.